InVitria Launches Optibumin® 25, the First Recombinant 25% Human Serum Albumin for Closed-System Biomanufacturing
InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only recombinant human serum albumin (rHSA) available as a 25% solution. Designed for closed-system workflows, Optibumin 25 is a high-purity alternative to plasma-derived albumin, enabling safer, more consistent manufacturing in cell and gene therapy applications.
